Bisoprolol for pericarditis -Phase III randomized controlled clinical trial in patients with acute or recurrent pericarditis

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523015-11-00

Acronym

BIP

Enrollment

300

Registered

2025-10-27

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pericarditis

Brief summary

The aim of this study is to evaluate the effectiveness of beta-blocking therapy with bisoprolol in reduce the persistence of pericarditis symptoms at 2 and 4 weeks and the frequency of relapses at 12 months

Detailed description

Secondary endpoints: persistence of symptoms at 1 month. Frequency of relapses at 12 months. Additional secondary analysis: correlation between baseline C-reactive protein values and heart rate at first observation

Interventions

DRUGBISOPROLOL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The aim of this study is to evaluate the effectiveness of beta-blocking therapy with bisoprolol in reduce the persistence of pericarditis symptoms at 2 and 4 weeks and the frequency of relapses at 12 months	—

Secondary

Measure	Time frame
Secondary endpoints: persistence of symptoms at 1 month. Frequency of relapses at 12 months. Additional secondary analysis: correlation between baseline C-reactive protein values and heart rate at first observation	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026